TY - JOUR
T1 - Infection Risk With Biologic Therapy in Patients With Inflammatory Bowel Disease
AU - Hindryckx, Pieter
AU - Novak, Gregor
AU - Bonovas, Stefanos
AU - Peyrin-Biroulet, Laurent
AU - Danese, Silvio
PY - 2017/10/1
Y1 - 2017/10/1
N2 - The development of biologic drugs revolutionized the management of inflammatory bowel diseases: Crohn's disease and ulcerative colitis. However, while their efficacy has been well established, it remains uncertain to what extent biologic treatments may be associated with important safety risks, such as serious infections, opportunistic infections, or tuberculosis reactivation. Herein, we review and discuss the current evidence on the infection risk associated with biologic therapy in patients with inflammatory bowel disease (IBD).
AB - The development of biologic drugs revolutionized the management of inflammatory bowel diseases: Crohn's disease and ulcerative colitis. However, while their efficacy has been well established, it remains uncertain to what extent biologic treatments may be associated with important safety risks, such as serious infections, opportunistic infections, or tuberculosis reactivation. Herein, we review and discuss the current evidence on the infection risk associated with biologic therapy in patients with inflammatory bowel disease (IBD).
UR - http://www.scopus.com/inward/record.url?scp=85029359748&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85029359748&partnerID=8YFLogxK
U2 - 10.1002/cpt.791
DO - 10.1002/cpt.791
M3 - Review article
C2 - 28699217
AN - SCOPUS:85029359748
SN - 0009-9236
VL - 102
SP - 633
EP - 641
JO - Clinical Pharmacology and Therapeutics
JF - Clinical Pharmacology and Therapeutics
IS - 4
ER -